dennis mccain
  • Home
  • Investing
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options

Best Ideas This Week

These companies are estimated to have a very nice one year total return on investment.

Home

Best Ideas 29 October 2017

10/29/2017

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
RCI Hospitality Holdings, Inc., through its subsidiaries, engages in the hospitality and related businesses in the United States. It operates in two segments, Nightclubs and Bombshells Restaurants/Sports Bars. The company owns and/or operates upscale adult nightclubs serving primarily businessmen and professionals under the Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, Jaguars Club, XTC Cabaret, Hoops Cabaret, Downtown Cabaret, Temptations, Silver City Cabaret, Foxy's Cabaret, Cabaret East, and The Seville brands. It also operates four restaurants/sports bars under the Bombshells brand; and a bar under the Studio 80 brand. As of December 13, 2016, the company operated 41 units that offers live adult entertainment, and/or restaurant and bar operations. In addition, it owns a national industry convention and tradeshow; 2 national industry trade publications; 2 national industry award shows; and approximately 25 industry Websites. The company was formerly known as Rick's Cabaret International, Inc. and changed its name to RCI Hospitality Holdings, Inc. in August 2014. RCI Hospitality Holdings, Inc. was founded in 1982 and is based in Houston, Texas.
​(Summary) (Company) (Chart)
29 October 2017
Price $27.16
1yr Target $32.50
Analysts 2
Dividend $0.12
Payout Ratio 10.61%

1yr Cap Gain 19.66%
Yield 0.44%
1yr Tot Return 20.10%

P/E 24.06
PEG 0.60
Beta 0.25


EPS (ttm) $1.13
EPS next yr $1.91
Forward P/E 14.24
EPS next 5yr 40.00%
1yr Price Support $76.40

Market Cap $258.02 Mil
Revenues $138.70 Mil
Earnings $10.90 Mil
Profit Margin 7.85%

Quick Ratio 0.90
Current Ratio 1.00
Debt/Equity 0.92


1yr RevGR -0.44%
3yr RevGR 6.25%
5yr RevGR 10.06%

1yr EarnGR 22.22%
3yr EarnGR 4.59%
5yr EarnGR 6.84%

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 3.80%
ROE 8.30%


Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
​(Summary) (Company) (Chart)
29 October 2017
Price $26.63
1yr Target $32.29
Analysts 7
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 21.25%
Yield 0.00%
1yr Tot Return 21.25%

P/E 140.90
PEG 3.06
Beta 1.91
​
EPS (ttm) $0.19
EPS next yr $0.67
Forward P/E 39.69
EPS next 5yr 46.00%
1yr Price Support $30.82

Market Cap $7.91 Bil
Revenues $319.70 Mil
Earnings $58.20 Mil
Profit Margin 18.20%

Quick Ratio 4.10
Current Ratio 4.10
Debt/Equity 0.00
​ 
1yr RevGR 415.04%
3yr RevGR 81.70%
5yr RevGR -7.95%

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 10.40%
ROE 59.70%
​
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
​​(Summary) (Company) (Chart)
29 October 2017
Price $150.11
1yr Target $179.56
Analysts 25
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 19.61%
Yield 0.00%
1yr Tot Return 19.61%

P/E 145.31
PEG 2.13
Beta 1.67
​
EPS (ttm) $1.03
EPS next yr $3.08
Forward P/E 48.80
EPS next 5yr 68.07%
1yr Price Support $209.65

Market Cap $37.84 Bil
Revenues $2.13 Bil
Earnings $259.50 Mil
Profit Margin 12.15%

Quick Ratio 3.50
Current Ratio 3.50
Debt/Equity 0.34
​
1yr RevGR 64.92%
3yr RevGR 11.88%
5yr RevGR 3.83%

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 8.80%
ROE 19.40%
​
0 Comments

Best Ideas 22 October 2017

10/22/2017

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
Applied Materials provides manufacturing equipment, services, and software to the semiconductor, display, and related industries worldwide. It operates through three segments: Semiconductor Systems, Applied Global Services, and Display and Adjacent Markets. The Semiconductor Systems segment develops, manufactures, and sells a range of manufacturing equipment used to fabricate semiconductor chips or integrated circuits. It offers products and technologies for transistor and interconnect fabrication, including epitaxy, ion implantation, oxidation and nitridation, rapid thermal processing, chemical vapor deposition, physical vapor deposition, chemical mechanical planarization, and electrochemical deposition; patterning, selective removal, and packaging products and systems that enable the transfer of patterns onto device structures; and metrology, inspection, and review systems for front- and back-end-of-line applications. The Applied Global Services segment provides integrated solutions to optimize equipment and fab performance and productivity, including spares, upgrades, services, remanufactured earlier generation equipment, and factory automation software for semiconductor, display, and other products. The Display and Adjacent Markets segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, and other display technologies for TVs, personal computers, tablets, smart phones, and other consumer-oriented devices, as well as equipment for flexible substrates. The company serves manufacturers of semiconductor wafers and chips, liquid crystal and other displays, and other electronic devices. Applied Materials, Inc. was founded in 1967 and is headquartered in Santa Clara, California.
(Summary) (Company) (Chart)
22 October 2017
Price $56.09
1yr Target $58.90
Analysts 20
Dividend $0.40
Payout Ratio 14.18%

1yr Cap Gain 5.00%
Yield 0.71%
1yr Tot Return 5.71%

P/E 19.91
PEG 0.70
Beta 1.83


EPS (ttm) $2.82
EPS next yr $3.66
Forward P/E 15.34
EPS next 5yr 28.63%
1yr Price Support $104.78

Market Cap $60.07 Bil
Revenues $13.87 Bil
Earnings $3.06 Bil
Profit Margin 22.06%

Quick Ratio 2.30
Current Ratio 2.90
Debt/Equity 0.61


1yr RevGR 12.07%
3yr RevGR 12.82%
5yr RevGR 0.57%

1yr EarnGR 37.50%
3yr EarnGR 92.99%
5yr EarnGR 1.21%

1yr DivGR 0.00%
3yr DivGR 0.83%
5yr DivGR 5.23%

ROA 18.20%
ROE 38.50%


Viking Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder. In addition, it develops VK0612, an orally available drug candidate for the treatment of type 2 diabetes; small molecule agonists of the erythropoietin receptor for the treatment of anemia; and tissue-selective inhibitors of diacylglycerol acyltransferase-1 for the treatment of obesity and dyslipidemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
(Summary) (Company) (Chart)
22 October 2017
Price $3.00
1yr Target $7.33
Analysts 3
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 144.33%
Yield 0.00%
1yr Tot Return 144.33%

P/E ---
PEG ---
Beta ---


EPS (ttm) $-0.83
EPS next yr $-0.80
Forward P/E ---
EPS next 5yr 40.00%
1yr Price Support ---

Market Cap $83.43 Mil
Revenues --- 
Earnings $-17.80 Mil
Profit Margin ---

Quick Ratio 4.30
Current Ratio 4.30
Debt/Equity 0.49


1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -91.30%
ROE -152.70%


0 Comments

Best Ideas 15 October 2017

10/15/2017

1 Comment

 
Picture
Here's a couple of stock ideas I'm looking at for next week. The first one is Walmart and it appears to have already started moving higher while GE hasn't found a bottom yet. Both are conservative established companies and currently pay a dividend.

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
Wal-Mart Stores, Inc. operates retail stores in various formats worldwide. It operates through three segments: Walmart U.S., Walmart International, and Sam's Club. The company operates discount stores, supermarkets, supercenters, hypermarkets, warehouse clubs, cash and carry stores, home improvement stores, specialty electronics stores, apparel stores, drug stores, convenience stores, and membership-only warehouse clubs; and retail Websites, such as walmart.com and samsclub.com, as well as mobile commerce applications. It offers grocery products, including meat, produce, natural and organics, deli and bakery, dairy, frozen foods, alcoholic and nonalcoholic beverages, floral and dry grocery, as well as consumables, such as health and beauty aids, baby products, household chemicals, paper goods, and pet supplies; and health and wellness products, which include pharmacy, optical services, clinical services, over-the-counter drugs, and other medical products. The company also provides electronics, cameras and supplies, photo processing services, cellular phones, cellular service plan contracts and prepaid service, movies, music, video games, and books; stationery, automotive, hardware and paint, sporting goods, and outdoor living and horticulture, as well as fabrics, crafts, and seasonal merchandise; apparel for women, girls, men, boys, and infants, as well as shoes, jewelry, and accessories; and home furnishings, housewares and small appliances, bedding, home decor, and toys. In addition, it offers fuel and financial services and related products, including money orders, prepaid cards, wire transfers, money transfers, check cashing, and bill payment. In addition, it offers brand name merchandise, including hardgoods, softgoods, and selected private-label items, such as Member's Mark. It operates 11,593 stores under 63 banners in 28 countries and e-commerce Websites in 11 countries. Wal-Mart Stores, Inc. was founded in 1945 and is headquartered in Bentonville, Arkansas.
(Summary) (Company) (Chart)
15 October 2017
Price $86.62
1yr Target $85.49
Analysts 29
Dividend $2.04
Payout Ratio 49.02%

1yr Cap Gain -1.31%
Yield 2.35%
1yr Tot Return 1.04%

P/E 20.84
PEG 4.43
Beta 0.32


EPS (ttm) $4.16
EPS next yr $4.62
Forward P/E 18.77
EPS next 5yr 4.70%
1yr Price Support $21.71

Market Cap $257.71 Bil
Revenues $490.01 Bil
Earnings $12.73 Bil
Profit Margin 2.59%

Quick Ratio 0.20
Current Ratio 0.80
Debt/Equity 0.62


1yr RevGR 0.77%
3yr RevGR 0.65%
5yr RevGR 1.70%

1yr EarnGR -4.16%
3yr EarnGR -4.24%
5yr EarnGR -0.63%

1yr DivGR 2.04%
3yr DivGR 2.06%
5yr DivGR 6.49%

ROA 6.30%
ROE 16.70%


General Electric Company operates as an infrastructure and technology company worldwide. Its Power segment offers gas and steam power systems; maintenance, service, and upgrade solutions; distributed power gas engines; water treatment, wastewater treatment, and process system solutions; and nuclear reactors, fuels, and support services. The company's Renewable Energy segment provides wind turbine platforms, and hardware and software; onshore and offshore wind turbines; and solutions, products, and services to hydropower industry. Its Oil & Gas segment offers surface and subsea drilling and production systems, and equipment for floating production platforms; and compressors, turbines, turboexpanders, reactors, industrial power generation, and auxiliary equipment. The company's Aviation segment designs and produces commercial and military aircraft engines, integrated digital components, and electric power and mechanical aircraft systems; and provides aftermarket services. Its Healthcare segment offers diagnostic imaging and clinical systems; products for drug discovery, biopharmaceutical manufacturing, and cellular technologies; and medical technologies, software, analytics, cloud solutions, and implementation services. The company's Transportation segment provides freight and passenger locomotives, and rail and support advisory services; and parts, integrated software solutions and data analytics, software-enabled solutions, mining equipment and services, and marine diesel and stationary power diesel engines and motors, as well as overhaul, repair and upgrade, and wreck repair services. Its Energy Connections & Lighting segment offers industrial, grid, power conversion, automation and control, lighting, and current solutions. The company's Capital segment provides industrial and energy financial services; and commercial aircraft leasing, financing, and consulting services. General Electric Company was founded in 1892 and is based in Boston, Massachusetts.
(Summary) (Company) (Chart)
15 October 2017
Price $22.98
1yr Target $28.00
Analysts 15
Dividend $0.96
Payout Ratio 110.34%

1yr Cap Gain 21.84%
Yield 4.17%
1yr Tot Return 26.01%

P/E 26.35
PEG 2.83
Beta 1.16
​
EPS (ttm) $0.87
EPS next yr $1.66
Forward P/E 13.87
EPS next 5yr 9.32%
1yr Price Support $15.47

Market Cap $199.26 Bil
Revenues $119.57 Bil
Earnings $7.77 Bil
Profit Margin 6.49%

Quick Ratio ---
Current Ratio ---
Debt/Equity 1.81

​
1yr RevGR 5.37%
3yr RevGR 2.95%
5yr RevGR -3.34%

1yr EarnGR ---
3yr EarnGR -11.08%
5yr EarnGR -6.27%

1yr DivGR 1.08%
3yr DivGR 5.53%
5yr DivGR 8.80%

ROA 2.00%
ROE 9.50%
​
1 Comment

Best Ideas 1/8 October 2017

10/8/2017

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
NVIDIA Corporation operates as a visual computing company worldwide. It operates in two segments, GPU and Tegra Processor. The GPU segment offers processors, which include GeForce for PC gaming; GeForce NOW for cloud-based game-streaming service; Quadro for design professionals working in computer-aided design, video editing, special effects, and other creative applications; Tesla for deep learning, accelerated computing, and general purpose computing; and GRID for cloud-based visual computing users. The Tegra Processor segment provides processors that integrate a computer onto a single chip under the Tegra brand name; DRIVE automotive computers, which offer self-driving capabilities; and tablet and portable devices for mobile gaming and TV streaming under the SHIELD name. The company's products are used in gaming, professional visualization, datacenter, and automotive markets. It sells its products primarily to original equipment manufacturers, original device manufacturers, system builders, motherboard manufacturers, add-in board manufacturers, and retailers/distributors. NVIDIA Corporation was founded in 1993 and is headquartered in Santa Clara, California.
(Summary) (Company) (Chart)
1 October 2017
Price $178.77
1yr Target $160.98
Analysts 32
Dividend $0.56
Payout Ratio 16.04%

1yr Cap Gain -9.96%
Yield 0.31%
1yr Tot Return -9.65%

P/E 51.18
PEG 3.96
Beta 1.26


EPS (ttm) $3.49
EPS next yr $3.97
Forward P/E 45.05
EPS next 5yr 12.92%
1yr Price Support $51.29

Market Cap $108.32 Bil
Revenues $8.34 Bil
Earnings $2.29 Bil
Profit Margin 27.45%

Quick Ratio 7.00
Current Ratio 7.80
Debt/Equity 0.35


1yr RevGR %
3yr RevGR %
5yr RevGR %

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA 23.90%
ROE 39.40%


Align Technology, Inc. designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services. The company's Clear Aligner segment offers Invisalign Full, a treatment used for a range of malocclusion; Invisalign Teen treatment that addresses orthodontic needs of teenage patients, such as compliance indicators, compensation for tooth eruption, and six free single arch replacement aligners; and Invisalign Assist treatment for anterior alignment and aesthetically-oriented cases. It also provides Invisalign Express (10 and 5) and Invisalign Lite/i7 treatments for orthodontic cases, non-comprehensive treatment relapse cases, or straightening prior to restorative or cosmetic treatments; Invisalign Go, a solution for general practitioner dentists (GPs) to identify and treat patients with mild malocclusion; SmileDirectClub aligners for minor tooth movement; custom clear aligner retainers used to maintain tooth position and correct minor relapse; and SmartTrack, a custom-engineered material that delivers force for orthodontic tooth movements. The company's Scanners and Services segment offers iTero Scanner, a single hardware platform with software options for restorative or orthodontic procedures; and Restorative software for iTero, a software for GPs, prosthodontists, periodontists, and oral surgeons. It also provides Orthodontic software for iTero, a software for orthodontists for digital records storage, orthodontic diagnosis, Invisalign digital impression submission, and for the fabrication of printed models and retainers; CAD/CAM services, such as iTero Models and Dies, OrthoCAD iCast, and OrthoCAD iRecord; and Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner, as well as third party scanners and digital scans for Invisalign treatment submission. The company was founded in 1997 and is headquartered in San Jose, California.
(Summary) (Company) (Chart)
1 October 2017
Price $186.27
1yr Target $194.45
Analysts 11
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 4.39%
Yield 0.00%
1yr Tot Return 4.39%

P/E 63.90
PEG 2.49
Beta 1.55
​
EPS (ttm) $2.92
EPS next yr $4.07
Forward P/E 45.78
EPS next 5yr 25.69%
1yr Price Support $104.55

Market Cap $14.80 Bil
Revenues $1.24 Bil
Earnings $237.60 Mil
Profit Margin 19.11%

Quick Ratio 2.30
Current Ratio 2.40
Debt/Equity 0.00
​
1yr RevGR %
3yr RevGR %
5yr RevGR %

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA 16.50%
ROE 23.20%
​
​Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
(Summary) (Company) (Chart)
1 October 2017
Price $19.30
1yr Target $15.40
Analysts 5
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain -20.21%
Yield 0.00%
1yr Tot Return -20.21%

P/E 96.50
PEG 1.32
Beta 2.12
​
EPS (ttm) $0.20
EPS next yr $0.70
Forward P/E 27.57
EPS next 5yr 73.20%
1yr Price Support $51.24

Market Cap $2.11 Bil
Revenues $108.70 Mil
Earnings $24.20 Mil
Profit Margin 22.26%

Quick Ratio 3.80
Current Ratio 4.00
Debt/Equity 0.07
​
1yr RevGR %
3yr RevGR %
5yr RevGR %

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA 33.00%
ROE 51.40%
0 Comments
    Picture
    Dennis McCain

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.

    Picture
    Top 100 Blogs for Dividend Investors

    Archives

    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Categories

    All

    RSS Feed

Powered by Create your own unique website with customizable templates.